HDRP Newsletter, June 2017

Message from the Associate Director

It’s summer in DC and with the increasing temperatures, we have several activities heating up here as well. In our last newsletter, we talked about our engagement on several efforts in response to the Cancer Moonshot’s Blue Ribbon Panel recommendations. I have been leading a DCCPS-wide group on symptom management research that has developed a concept focused on improving assessment and management of common symptoms as part of routine clinical practice. Several of my HDRP colleagues have been working with others in DCCPS to shape other concepts, including one on accelerating colorectal cancer screening and follow-up through implementation science, another on developing new approaches to identifying and caring for individuals with inherited cancer syndromes, and yet another on evaluating ways to analyze patient-reported outcomes data. These concepts, along with many others being proposed throughout NCI, were presented at the joint Board of Scientific Advisors/National Cancer Advisory Board meeting on June 20-21, 2017. All four were approved and the next step will be drafting and publishing the official notice of funding opportunity (NOFO). Continuing with the fast pace of Cancer Moonshot activities, we anticipate making initial awards in fiscal year 2018.

Elsewhere around the program, we held our third annual staff retreat at the end of last month and it was a great success. We spent the day taking a step back to reflect on our core identity as a group and how we can best work together to advance the science of healthcare delivery. We thought about cross-cutting research themes that should be a priority for development over the next several years and discussed processes for reviewing and reinvigorating some of our existing initiatives. As with any opportunity to step outside the daily routine, this retreat left us with renewed vigor and dedication for working to improve cancer care delivery. I encourage you to subscribe to our listserv and follow us on Twitter/X to stay up-to-date on all of our ongoing activities.

Sincerely,
Paul Jacobsen, PhD

Spotlight on… Financial Burden

The growth of lay media coverage and expanding scientific literature has drawn greater attention to the burden that many patients face because of their cancer care costs. There is a growing body of evidence that financial burden is associated with diminished quality of life and increased mortality. NCI includes financial burden as a topic in the PDQ® series aimed at health professional education and in materials aimed at assisting patients.

At our recent HDRP retreat, financial burden emerged as an important topic that cuts across all the research areas in our portfolio. We recognized the need to invest more staff time and effort in coordinating our existing activities and establishing priorities for future initiatives. A small working group has begun to develop a plan that will be vetted internally at the end of the year. Stay tuned for opportunities to engage with us on this topic in spring of 2018.

In the meantime, we want the research community to know that we are strongly committed to research on this topic, particularly testing interventions designed to alleviate financial burden. Investigators preparing applications in this area should be sure to confirm that their proposed activities fall within the NIH priorities described the Guide Notice Clarifying NIH Priorities for Health Economics Research (NOT-OD-16-025).

We also want to call your attention to several active notice of funding opportunities within the division that address this important area, including:

• Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (PA-17-060/PA-17-061)
• Examination of Survivorship Care Planning Efficacy and Impact (PA-16-012/PA-16-011)
• Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (PA-17-109/PA-17-110)
• Dissemination and Implementation Research in Health (PAR-16-238/PAR-16-236/PAR-16-237)
• Multilevel Interventions in Cancer Care Delivery: Building from the Problem of Follow-up to Abnormal Screening Tests (PAR-17-146)

HDRP staff welcome the opportunity to consult with investigators about financial burden research and any related notices or notice of funding opportunities.

Updates

• Data Resource: The Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) linked database is a population-based data resource that contains information about health-related quality of life and other patient-reported outcomes among older adult (ages 65+) and disabled Medicare Advantage beneficiaries with and without cancer. With the addition of data from cohort 15, SEER-MHOS now contains data on over 140,000 cancer patients, which is an increase of over 20,000 cancer patients from the prior linkage. The database also includes over 2 million MHOS beneficiaries with no history of cancer. For more information, please visit the SEER-MHOS webpage.
• Data Resource: The Surveillance, Epidemiology and End Results - Medicare Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) data linkage includes patient survey, cancer registry, and medical claims information. Publicly available since December 2016, SEER-CAHPS is a great resource for quality of care research. To learn more about this resource, please visit our SEER-CAHPS page, which includes a webinar (under the Support for Researchers section) that provides an overview of the data, including its uses, applications, and the process to obtain it.
• Data Resource: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE^™), which is a is a patient-reported outcome measurement tool developed to evaluate symptomatic toxicity in patients on cancer clinical trials, is now available in seven languages. Available languages include English, Danish, German, Japanese, Spanish, Korean, and Italian. Other language translations are still in development and should be available in early 2018. For more information about this tool, please visit our PRO-CTCAE page.
• Webinar Series: The Healthcare Teams Cyber Discussion Series explores how healthcare teams utilize Health Information Technology (HIT) to improve cancer care delivery. These sessions feature a live presentation with nationally recognized subject matter experts followed by interactive discussion. The schedule for the remainder of the year includes discussions on care coordination, cancer care teams, and management of interdependent care. The next cyber discussion is scheduled for November 9. You can find a full schedule of webinars on our Events and Media page.
• Webinar Series: The Outcomes Research Branch Virtual Speaker Series addresses contemporary challenges in cancer outcomes research, including knowledge generation, translation into practice, and conceptual, methodologic and technologic developments. This quarterly series brings together investigators, clinicians, policy makers and other stakeholders and includes presentations followed by Q&A. The next speaker series presentation is still being planned. Check our Events and Media page for updates.
• Funding: The Healthcare Delivery Research Program along with the Behavioral Research Program and Epidemiology and Genomics Research Program, hosted a webinar on May 9, 2017 to review the Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery notice of funding opportunity (R01/R21). A recording of the webinar, slides, and FAQ, are available on our Events and Media page under Archived Webinars.
• On the web: Interested in learning more about Cancer Care Delivery Research within the NCI Community Oncology Research Program (NCORP)? We now have a webpage that provides an overview.

Funding Opportunities

Several notice of funding opportunities (NOFOs) with relevance to healthcare delivery research are mentioned below. For a full list of open announcements across the Division of Cancer Control and Population Sciences, please visit the DCCPS Funding Opportunities page. Be sure to also look for funding opportunities available across NCI that may be applicable to your areas of research.

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers s (R01/R21)

This NOFO seeks to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01/R21)

The purpose of this NOFO is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01/R21)

The purpose of this NOFO is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01/R21)

This NOFO invites applications for intervention research designed to support caregivers of adult cancer patients.

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01/R03/R21)

This NOFO encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine.

Multilevel Interventions in Cancer Care Delivery: Building from the Problem of Follow-up to Abnormal Screening Tests (U01)

This NOFO encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers.

Summer Fellows

Staff Publications, January - June 2017

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys 2017 Jun 1;98(2):409-418. [View Abstract]

Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, Kent EE, Jacobsen PB, Lee SJ, Hsieh MM, Denzen EM, Syrjala KL. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. Biol Blood Marrow Transplant 2017 Apr;23(4):538-551. [View Abstract]

Bluethmann SM, Murphy CC, Tiro JA, Mollica MA, Vernon SW, Bartholomew LK. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. Oncol Nurs Forum 2017 May 1;44(3):E101-E110. doi: 10.1188/17.ONF.E101-E110. [View Abstract]

Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol 2017 Jan 3:JCO2016694166. [Epub ahead of print] [View Abstract]

Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB. Use of High-cost Systemic Treatments in Elderly mCRC Patients. Med Care 2017 Jan;55(1):86-87. [Look up in PubMed]

Chollette V, Beasley DD, Abdiwahab E, Taplin S. Health Information Systems Approach to Managing Task Interdependence in Cancer Care Teams. J Oncol Pract 2017 Mar;13(3):154-156. [Look up in PubMed]

de Moor JS, Dowling EC, Ekwueme DU, Guy GP Jr, Rodriguez J, Virgo KS, Han X, Kent EE, Li C, Litzelman K, McNeel TS, Liu B, Yabroff KR. Employment implications of informal cancer caregiving. J Cancer Surviv 2017 Feb;11(1):48-57. [View Abstract]

Enewold L, Sharon E, Harlan LC. Metastatic Melanoma: Treatment and Survival in the U.S. after the Introduction of Ipilimumab and Vemurafenib. Oncol Res Treat 2017;40(4):174-183. [View Abstract]

Geiger AM. Symptom Management: War Problems, Moonshot Solutions? J Natl Cancer Inst 2017 Apr 1;109(4). [Look up in PubMed]

Halpern MT, Urato MP, Kent EE. The health care experience of patients with cancer during the last year of life: Analysis of the SEER-CAHPS data set. Cancer 2017 Jan 1;123(2):336-344. [View Abstract]

Hamilton JG, Abdiwahab E, Edwards HM, Fang ML, Jdayani A, Breslau ES. Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J Gen Intern Med 2017 Mar;32(3):315-324. [View Abstract]

Hays RD, Chawla N, Kent EE, Arora NK. Measurement equivalence of the Consumer Assessment of Healthcare Providers and Systems (CAHPS^®) Medicare survey items between Whites and Asians. Qual Life Res 2017 Feb;26(2):311-318. [View Abstract]

Jacobsen PB. New Challenges in Psycho-Oncology Research II: A health care delivery, dissemination, and implementation research model to promote psychosocial care in routine cancer care. Psychooncology 2017 Apr;26(4):419-423. [Look up in PubMed]

Jensen RE, Potosky AL, Moinpour CM, Lobo T, Cella D, Hahn EA, Thissen D, Smith AW, Ahn J, Luta G, Reeve BB. United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer. J Clin Oncol 2017 Jun 10;35(17):1913-1920. [View Abstract]

Jensen RE, Moinpour CM, Potosky AL, Lobo T, Hahn EA, Hays RD, Cella D, Smith AW, Wu XC, Keegan TH, Paddock LE, Stroup AM, Eton DT. Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort. Cancer 2017 Jan 1;123(2):327-335. [View Abstract]

Kaniski F, Enewold L, Thomas A, Malik S, Stevens JL, Harlan LC. Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010. Lung Cancer 2017 Jan;103:66-74. [View Abstract]

Knoerl R, Gray E, Stricker C, Mitchell SA, Kippe K, Smith G, Dudley WN, Lavoie Smith EM. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer 2017 Jun 2. [Epub ahead of print] [View Abstract]

Kobrin S, Rendle KA. Principles for being theoretical-Increasing the impact of research conducted in primary care. Eur J Cancer Care (Engl). 2017 May;26(3). [View Abstract]

Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP. Clinical Activity of the ?-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol 2017 May 10;35(14):1561-1569. [View Abstract]

Lee MS, Small BJ, Jacobsen PB. Rethinking barriers: a novel conceptualization of exercise barriers in cancer survivors. Psychol Health Med 2017 May 4:1-8. [Epub ahead of print] [View Abstract]

Litzelman K, Kent EE, Rowland JH. Interrelationships Between Health Behaviors and Coping Strategies Among Informal Caregivers of Cancer Survivors. Health Educ Behav 2017 Apr 1:1090198117705164. [Epub ahead of print] [View Abstract]

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E. Evaluation of different recall periods for the U.S. National Cancer Institute's PRO-CTCAE. Clin Trials 2017 Jun;14(3):255-263. [View Abstract]

Moinpour CM, Donaldson GW, Davis KM, Potosky AL, Jensen RE, Gralow JR, Back AL, Hwang JJ, Yoon J, Bernard DL, Loeffler DR, Rothrock NE, Hays RD, Reeve BB, Smith AW, Hahn EA, Cella D. The challenge of measuring intra-individual change in fatigue during cancer treatment. Qual Life Res 2017 Feb;26(2):259-271. [View Abstract]

Randhawa GS, Ahern DK, Hesse BW. Information technology-enabled team-based, patient-centered care: the example of depression screening and management in cancer care. Health Policy Technol 2017 Mar;6(1):67-71.

Shaw BE, Hahn T, Martin PJ, Mitchell SA, Petersdorf EW, Armstrong GT, Shelburne N, Storer BE, Bhatia S. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. Biol Blood Marrow Transplant 2017 Jan;23(1):10-23. Review. [View Abstract]

Spain P, Teixeira-Poit S, Halpern MT, Castro K, Prabhu Das I, Adjei B, Lewis R, Clauser SB. The National Cancer Institute Community Cancer Centers Program (NCCCP): Sustaining Quality and Reducing Disparities in Guideline-Concordant Breast and Colon Cancer Care. Oncologist 2017 May 9. pii: theoncologist.2016-0252. [Epub ahead of print] [View Abstract]

Warren JL, Harlan LC, Trimble EL, Stevens J, Grimes M, Cronin KA. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study. Gynecol Oncol 2017 Jun;145(3):486-492. [View Abstract]

White A, Thompson TD, White MC, Sabatino SA, de Moor J, Doria-Rose PV, Geiger AM, Richardson LC. Cancer Screening Test Use - United States, 2015. MMWR Morb Mortal Wkly Rep 2017 Mar 3;66(8):201-206. doi: 10.15585/mmwr.mm6608a1. [View Abstract]